EPO and anemia (phenotype): Novel developments in the pharmacologic treatment of anemia such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which stimulate endogenous EPO expression via the HIF signaling pathway, may also profit from these insights as the model can be easily adapted to the much different dosing frequencies of HIF-PHIs (typically several times a week).